{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:05:00Z","timestamp":1788267900933,"version":"build-2803163510"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.eururo.2024.09.004","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T02:47:02Z","timestamp":1727837222000},"page":"79-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Sample Site Impacts RNA Biomarkers for Renal Cell Carcinoma"],"prefix":"10.1016","volume":"87","author":[{"given":"Lennert","family":"Eismann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy X.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cerise","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ostrovnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshen","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ari Hakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"Reznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh R.","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.09.004_b0005","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2024.09.004_b0010","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2024.09.004_b0015","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2024.09.004_b0020","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2024.09.004_b0025","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(22)00128-0","article-title":"Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial","volume":"23","author":"Vano","year":"2022","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2024.09.004_b0030","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/oncolo\/oyad216.023","article-title":"Optimal treatment by invoking biologic clusters in renal cell carcinoma (OPTIC RCC)","volume":"28","author":"Beckermann","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2024.09.004_b0035","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178915","article-title":"Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles","volume":"134","author":"Barata","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2024.09.004_b0040","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","article-title":"Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes","volume":"42","author":"Saliby","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2024.09.004_b0045","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824025958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824025958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T22:36:20Z","timestamp":1741905380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824025958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0302283824025958"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.004","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sample Site Impacts RNA Biomarkers for Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}